Pipeline

//Pipeline
Pipeline 2018-02-04T11:43:31+00:00

Diverse, promising pipeline of targeted cytotoxic drugs and immunotherapies for multiple oncology indications

Targeted Cytotoxic DSPs: two lead programs targeting apoptotic TNF-SF ligands to tumor site, focusing on lymphoma (KAHR-102) and solid tumors (KAHR-101)

Targeted Immunotherapeutic DSPs: early stage programs utilizing immune cell activating TNF-SF ligands, aimed at recruiting and stimulating immune activity in the tumor microenvironment (KAHR-105, KAHR-106, KAHR-107)

Pipeline
KAHR-102
KAHR-101
KAHR-105
KAHR-106
KAHR-107